Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
26 hedge funds and large institutions have $28M invested in Agile Therapeutics in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
19,200% more call options, than puts
Call options by funds: $386K | Put options by funds: $2K
412% more capital invested
Capital invested by funds: $5.47M → $28M (+$22.5M)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$8.93M |
| 2 |
Renaissance Technologies
New York
|
+$206K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
+$138K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$110K |
| 5 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$106K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$57.2K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$19.1K |
| 3 |
Morgan Stanley
New York
|
-$12.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.36K |
| 5 |
JGC
J. Goldman & Co
New York
|
-$6K |
AGRX Hedge Fund Activity: Q1 2019 in Review
26 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q1 2019, worth a combined $28M — up 412% from $5.47M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AGRX positions and 4 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $8.93M. The largest seller was Fosun International, cutting an estimated $57.2K.
- 26 institutional investors held Agile Therapeutics (AGRX) as of Q1 2019, up from 25 in Q4 2018.
- Funds reported $28M of Agile Therapeutics stock for Q1 2019, up 412% quarter-over-quarter.
- 5 funds opened new Agile Therapeutics positions in Q1 2019 and 4 closed out, a net change of +1 holder.
- The largest Agile Therapeutics buyer in Q1 2019 was Perceptive Advisors, an estimated $8.93M added.
- The largest Agile Therapeutics seller in Q1 2019 was Fosun International, an estimated $57.2K sold.
Based on aggregated 13F filings for Q1 2019.